At AbTherx we are redefining therapeutic antibody discovery, driven by our passion for creating best-in-class therapeutics by advancing reliable, scalable transgenic technologies grounded in rigorous science.

We are (i) seeking 1-2 strategic partnerships for antibody discovery for challenging targets such as GPCRs, ion channels or targeting buried epitopes using our Fully Human Long CDR3 technology, (ii) broadly seeking partners to in-license our transgenic antibody discovery platform for multi-specifics using our patent-pending Common Light Chain and (iii) licensing and co-development opportunities for our novel CD3 binders to create T cell engagers.

We strive to increase overall access to best in class transgenics for antibody discovery, offering a range of terms tailored to each partner, ranging from standard licensing to milestone- and royalty-free options. Whether you’re a startup or a global biotech leader, we bring a collaborative mindset to empower your innovative pipeline.